Bayer's September Calendar Tightens: A $7.25 Billion Settlement Hearing, a Cardiology Showcase, and a Debt Milestone All Converge
Published on 08/22/2026 at 17:42 | Redaktion boerse-global.de
The German pharmaceutical and agrochemical group enters the autumn with an unusually crowded agenda. Between a rescheduled US court hearing on its landmark glyphosate settlement, a major data readout at a European cardiology congress, and the closing of a €3 billion minority investment from Apollo, the next six weeks will test whether Bayer can convert operational momentum into a lasting re-rating of its shares.
The stock closed Friday at €47.90, down 0.9% on the day, even as the company delivered two pieces of positive news in a single session. The pullback was attributed to fresh uncertainty in the Roundup litigation, where a hearing on final approval of the proposed $7.25 billion class-action settlement has been pushed back once again — this time to September 14, 2026, from an earlier date of August 19.
A Legal Clock That Keeps Sliding
The postponement stems from additional processing time needed for opt-out requests following the US Supreme Court's late-June ruling, which sided with Bayer by a 7-to-2 vote. That decision declared state-level lawsuits over inadequate warning labels preempted by federal law under FIFRA, removing a significant layer of legal exposure.
For investors, each delay in the glyphosate saga tends to reignite anxiety. The final resolution of these litigation risks is widely viewed as the single most important catalyst for a sustainable revaluation of the stock. The shares nonetheless remain firmly in positive territory: up 29% year-to-date and 72% over the past twelve months, though they sit roughly 11% below the 52-week high of €53.86 reached on July 3.
Apollo Deal Reshapes the Balance Sheet Outlook
The legal calendar is not the only moving part. Bayer's second-quarter results, published alongside the debt-reduction acceleration, showed a group that is making tangible progress on its financial commitments. Net financial debt at year-end is now projected at €29–30 billion, down from a prior guidance range of €32–33 billion.
Should investors sell immediately? Or is it worth buying Bayer?
The improvement is largely attributable to the Apollo transaction, announced in July, under which Apollo-managed funds will inject €3.0 billion into a newly established entity in exchange for a minority stake without control rights. Bayer retains majority ownership and operational control of its long-acting reversible contraception (LARC) business. The deal is expected to close in the third quarter of 2026.
Quarterly revenue reached €10.87 billion, a like-for-like increase of 2.2%, while adjusted EBITDA rose 1.9% to €2.14 billion. Crop Science again carried the group, with adjusted earnings jumping 30.2%, while the pharma division lagged with a 3.6% decline — though Nubeqa, the oncology drug, contributed €820 million in quarterly sales. Net income swung to €219 million from a loss of €199 million a year earlier, even as core earnings per share fell 16.7% to €0.95. For the first half, group sales came to €24.277 billion, up 3.3% on an adjusted basis, with core EPS of €3.66.
Management has held its full-year guidance: adjusted EBITDA of €9.6–10.1 billion and core EPS of €4.30–4.90.
Analysts Move Targets Higher
The combination of a stronger balance sheet trajectory and solid operational numbers has prompted several banks to revise their price targets. UBS lifted its target on August 5 from €52 to €62, maintaining a "Buy" rating. Goldman Sachs holds the most bullish view among the houses cited, with a €63.50 target. The DZ Bank raised its fair value on August 4 from €54 to €60, keeping a "Kaufen" recommendation, while JPMorgan reaffirmed "Overweight" with a €50 target the same day.
A Milestone Payment and a Cardiology Showcase
Friday also brought news from both ends of the business. Bayer confirmed it had made the first milestone payment under its collaboration with MustGrow Biologics, a partnership dating back to late 2023 focused on mustard-based biocontrol technologies for soil protection. The agreement, which grants Bayer exclusive rights across Europe, the Middle East and Africa, carries a total value of $35–40 million spread over five to seven years. The initial payment signals that the technology has cleared an early development hurdle, consistent with Crop Science's push into sustainable biological solutions.
On the pharma side, the company will present eleven scientific abstracts at the European Society of Cardiology congress in Munich from August 28 to 31. The centerpiece is new Phase III data on Kerendia (finerenone) in chronic kidney disease, alongside results for the investigational agent asundexian. Particular attention will focus on the pooled INFINITY analysis, which examines how Kerendia performs in patients with and without atherosclerotic cardiovascular disease. The cardiovascular pipeline is considered one of Bayer's most important growth engines, and a positive readout could provide fresh tailwinds for the pharma division.
Chart Holds, for Now
Technically, the stock remains in a constructive position, trading 2.4% above its 50-day moving average of €46.78. The relative strength index at 50.1 points to a neutral stance — neither overbought nor oversold.
With the next quarterly report scheduled for November 3, the immediate focus shifts to the ESC presentations and the September 14 court date. Both events carry the potential to move the shares meaningfully, though in opposite directions. For a company that has spent years trying to draw a line under its litigation legacy, the coming weeks will show whether the market is finally ready to look past Roundup — or whether the legal overhang will keep capping the rally.
Ad
Bayer Stock: New Analysis - 22 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
